Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Evaluate the Safety of RC88 for Injection in Patients With Advanced Malignant Solid Tumors,Multicenter, Open, Multi-cohort Extension of Efficacy and Pharmacokinetic Characteristics Phase I /IIa Clinical Study

NCT04175847 is registered in ClinicalTrials.gov with RemeGen Co., Ltd. as lead sponsor.

NCT NCT04175847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04175847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Evaluate the Safety of RC88 for Injection in Patients With Advanced Malignant Solid Tumors,Multicenter, Open, Multi-cohort Extension of Efficacy and Pharmacokinetic Characteristics Phase I /IIa Clinical Study
Lead sponsor
RemeGen Co., Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
April 14, 2020
Completion date
December 31, 2025
Enrollment
198 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor